Article Text

Extended report
Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
  1. Yoshiya Tanaka1,
  2. Shintaro Hirata1,
  3. Satoshi Kubo1,
  4. Shunsuke Fukuyo1,
  5. Kentaro Hanami1,
  6. Norifumi Sawamukai1,
  7. Kazuhisa Nakano1,
  8. Shingo Nakayamada1,
  9. Kunihiro Yamaoka1,
  10. Fusae Sawamura2,
  11. Kazuyoshi Saito1
  1. 1The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
  2. 2Medical Department, AbbVie GK, Tokyo, Japan
  1. Correspondence to Professor Yoshiya Tanaka, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi, Kitakyushu 807-8555, Japan; tanaka{at}med.uoeh-u.ac.jp

Statistics from Altmetric.com

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles